Fundamental Analysis of PROQR THERAPEUTICS NV(NASDAQ:PRQR) stock

Fundamental Rating

We assign a fundamental rating of 2 out of 10 to PRQR. PRQR was compared to 565 industry peers in the Biotechnology industry. PRQR may be in some trouble as it scores bad on both profitability and health. PRQR is quite expensive at the moment. It does show a decent growth rate.

Quickly go to:

1. Profitability

1.1 Basic Checks

PRQR had negative earnings in the past year.

PRQR had a negative operating cash flow in the past year.

PRQR had negative earnings in each of the past 5 years.

In the past 5 years PRQR reported 4 times negative operating cash flow.

1.2 Ratios

PRQR's Return On Assets of -18.25% is amongst the best of the industry. PRQR outperforms 81.11% of its industry peers.

PRQR has a Return On Equity of -65.57%. This is comparable to the rest of the industry: PRQR outperforms 58.65% of its industry peers.

		Industry Rank	Sector Rank
ROA	-18.25%
ROE	-65.57%
ROIC	N/A

ROA(3y)-29.27%

ROA(5y)-36.61%

ROE(3y)-73.83%

ROE(5y)-72.59%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

PRQR does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

PRQR does not have a ROIC to compare to the WACC, probably because it is not profitable.

Compared to 1 year ago, PRQR has about the same amount of shares outstanding.

Compared to 5 years ago, PRQR has more shares outstanding

Compared to 1 year ago, PRQR has a worse debt to assets ratio.

2.2 Solvency

PRQR has an Altman-Z score of -2.21. This is a bad value and indicates that PRQR is not financially healthy and even has some risk of bankruptcy.

The Altman-Z score of PRQR (-2.21) is comparable to the rest of the industry.

A Debt/Equity ratio of 0.40 indicates that PRQR is not too dependend on debt financing.

PRQR has a Debt to Equity ratio of 0.40. This is in the lower half of the industry: PRQR underperforms 72.01% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0.4
Debt/FCF	N/A
Altman-Z	-2.21

ROIC/WACCN/A

WACC6.95%

2.3 Liquidity

A Current Ratio of 2.73 indicates that PRQR has no problem at all paying its short term obligations.

PRQR has a worse Current ratio (2.73) than 67.56% of its industry peers.

PRQR has a Quick Ratio of 2.73. This indicates that PRQR is financially healthy and has no problem in meeting its short term obligations.

PRQR has a worse Quick ratio (2.73) than 66.49% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	2.73
Quick Ratio	2.73

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 34.09% over the past year.

PRQR shows a strong growth in Revenue. In the last year, the Revenue has grown by 98.44%.

PRQR shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 10.58% yearly.

EPS 1Y (TTM)34.09%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-42.86%

Revenue 1Y (TTM)98.44%

Revenue growth 3Y0.26%

Revenue growth 5Y10.58%

Sales Q2Q%180.51%

3.2 Future

The Earnings Per Share is expected to decrease by -15.78% on average over the next years. This is quite bad

Based on estimates for the next years, PRQR will show a very strong growth in Revenue. The Revenue will grow by 22.64% on average per year.

EPS Next Y10.57%

EPS Next 2Y-13.48%

EPS Next 3Y-15.78%

EPS Next 5YN/A

Revenue Next Year51.71%

Revenue Next 2Y17.63%

Revenue Next 3Y-3.14%

Revenue Next 5Y22.64%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

PRQR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for PRQR. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

PRQR's earnings are expected to decrease with -15.78% in the coming years. This may justify a cheaper valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-13.48%

EPS Next 3Y-15.78%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for PRQR!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

PROQR THERAPEUTICS NV

NASDAQ:PRQR (11/22/2024, 8:00:00 PM)

After market: 3.62 0 (0%)

3.62

+0.01 (+0.28%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap383.36M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-18.25%
ROE	-65.57%
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.16

Health

		Industry Rank	Sector Rank
Debt/Equity	0.4
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	2.73
Quick Ratio	2.73
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

High Growth Momentum

Growth

EPS 1Y (TTM)34.09%

EPS 3YN/A

EPS 5Y

EPS Q2Q%

EPS Next Y10.57%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)98.44%

Revenue growth 3Y0.26%

Revenue growth 5Y

Sales Q2Q%

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

PROQR THERAPEUTICS NV (PRQR)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens